Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models

T Andoh; T Fujimoto; T Sudo; I Fujita; M Imabori; H Moritake; T Sugimoto; Y Sakuma; T Takeuchi; S Kawabata; M Kirihata; T Akisue; K Yayama; M Kurosaka; S Miyatake; Y Fukumori; H Ichikawa

doi:10.1016/j.apradiso.2011.02.005

Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models

Appl Radiat Isot. 2011 Dec;69(12):1721-4. doi: 10.1016/j.apradiso.2011.02.005. Epub 2011 Mar 1.

Authors

T Andoh¹, T Fujimoto, T Sudo, I Fujita, M Imabori, H Moritake, T Sugimoto, Y Sakuma, T Takeuchi, S Kawabata, M Kirihata, T Akisue, K Yayama, M Kurosaka, S Miyatake, Y Fukumori, H Ichikawa

Affiliation

¹ Laboratory of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe, Japan.

PMID: 21367607
DOI: 10.1016/j.apradiso.2011.02.005

Abstract

Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of (10)B (45-74 ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of L-BPA-fructose complex (500 mg BPA/kg).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Animals
Boron Compounds / pharmacokinetics*
Boron Neutron Capture Therapy*
Cell Line, Tumor
Female
Humans
Mice
Mice, Inbred BALB C
Mice, Nude
Phenylalanine / analogs & derivatives*
Phenylalanine / pharmacokinetics
Sarcoma, Clear Cell / metabolism
Sarcoma, Clear Cell / radiotherapy*
Tissue Distribution

Substances

Boron Compounds
Phenylalanine
4-boronophenylalanine